Human Immunodeficiency Virus gag and protease: Partners in resistance

Retrovirology

Volumn 9, Issue , 2012, Pages

  Fun, Axel ^a   Wensing, Annemarie M J ^a   Verheyen, Jens ^b   Nijhuis, Monique ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b UNIVERSITY OF COLOGNE   (Germany)

Author keywords

Cross resistance; Gag mutations; HIV; Maturation inhibitors; Particle maturation; Protease inhibitors; Resistance

Indexed keywords

AMPRENAVIR; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; ATAZANAVIR; BEVIRIMAT; CA ASSEMBLY INHIBITOR; CA P2 INHIBITOR; DARUNAVIR; FOSAMPRENAVIR; GAG PROTEIN; HUMAN IMMUNODEFICIENCY VIRUS PROTEINASE; HUMAN IMMUNODEFICIENCY VIRUS PROTEINASE INHIBITOR; INDINAVIR; LOPINAVIR; MATURATION INHIBITOR; MPC 426; MPC 9055; MPI 461359; NELFINAVIR; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; PA 1050040; PF 46396; POLYPROTEIN; PROTEIN PRECURSOR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; TIPRANAVIR; UNCLASSIFIED DRUG; VIVECON; POL PROTEIN;

CROSS RESISTANCE; DRUG BIOAVAILABILITY; DRUG EXPOSURE; DRUG MECHANISM; ENZYME SUBSTRATE; GENOTYPE; HUMAN IMMUNODEFICIENCY VIRUS; IN VITRO STUDY; IN VIVO STUDY; LIFE CYCLE STAGE; MOLECULAR EVOLUTION; NONHUMAN; PROTEIN DEGRADATION; PROTEIN POLYMORPHISM; PROTEIN PROCESSING; REVIEW; VIRAL PHENOMENA AND FUNCTIONS; VIRUS MATURATION; VIRUS MUTATION; VIRUS PARTICLE; VIRUS RESISTANCE; ANTIVIRAL RESISTANCE; BINDING SITE; DRUG EFFECT; ENZYMOLOGY; GENETIC SELECTION; GENETIC VARIABILITY; GENETICS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; METABOLISM; MUTATION; PHYSIOLOGY; VIROLOGY; VIRUS REPLICATION;

HUMAN IMMUNODEFICIENCY VIRUS;

BINDING SITES; DRUG RESISTANCE, VIRAL; EVOLUTION, MOLECULAR; GAG GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS; GENETIC VARIATION; HIV INFECTIONS; HIV PROTEASE; HIV PROTEASE INHIBITORS; HIV-1; HUMANS; MUTATION; POL GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS; SELECTION, GENETIC; VIRUS REPLICATION;

EID: 84864505786     PISSN: None     EISSN: 17424690     Source Type: Journal    
DOI: 10.1186/1742-4690-9-63     Document Type: Review

References (127)

1. Jacks T, Power MD, Masiarz FR, Luciw PA, Barr PJ, Varmus HE. Characterization of ribosomal frameshifting in HIV-1 gag-pol expression. Nature 1988, 331:280-283. 10.1038/331280a0, 2447506.
2. Prabu-Jeyabalan M, Nalivaika E, Schiffer CA. Substrate shape determines specificity of recognition for HIV-1 protease: analysis of crystal structures of six substrate complexes. Structure 2002, 10:369-381. 10.1016/S0969-2126(02)00720-7, 12005435.
3. Krausslich HG, Ingraham RH, Skoog MT, Wimmer E, Pallai PV, Carter CA. Activity of purified biosynthetic proteinase of human immunodeficiency virus on natural substrates and synthetic peptides. Proc Natl Acad Sci U S A 1989, 86:807-811. 10.1073/pnas.86.3.807, 286566, 2644644.
4. Pettit SC, Moody MD, Wehbie RS, Kaplan AH, Nantermet PV, Klein CA, Swanstrom R. The p2 domain of human immunodeficiency virus type 1 Gag regulates sequential proteolytic processing and is required to produce fully infectious virions. J Virol 1994, 68:8017-8027. 237265, 7966591.
5. Wiegers K, Rutter G, Kottler H, Tessmer U, Hohenberg H, Krausslich HG. Sequential steps in human immunodeficiency virus particle maturation revealed by alterations of individual Gag polyprotein cleavage sites. J Virol 1998, 72:2846-2854. 109729, 9525604.
6. Pettit SC, Lindquist JN, Kaplan AH, Swanstrom R. Processing sites in the human immunodeficiency virus type 1 (HIV-1) Gag-Pro-Pol precursor are cleaved by the viral protease at different rates. Retrovirology 2005, 2:66. 10.1186/1742-4690-2-66, 1291402, 16262906.
7. Ozen A, Haliloglu T, Schiffer CA. Dynamics of preferential substrate recognition in HIV-1 protease: redefining the substrate envelope. J Mol Biol 2011, 410:726-744. 10.1016/j.jmb.2011.03.053, 3139114, 21762811.
8. Pettit SC, Henderson GJ, Schiffer CA, Swanstrom R. Replacement of the P1 amino acid of human immunodeficiency virus type 1 Gag processing sites can inhibit or enhance the rate of cleavage by the viral protease. J Virol 2002, 76:10226-10233. 10.1128/JVI.76.20.10226-10233.2002, 136535, 12239298.
9. Maguire MF, Guinea R, Griffin P, Macmanus S, Elston RC, Wolfram J, Richards N, Hanlon MH, Porter DJ, Wrin T, Parkin N, Tisdale M, Furfine E, Petropoulos C, Snowden BW, Kleim JP. Changes in human immunodeficiency virus type 1 Gag at positions L449 and P453 are linked to I50V protease mutants in vivo and cause reduction of sensitivity to amprenavir and improved viral fitness in vitro. J Virol 2002, 76:7398-7406. 10.1128/JVI.76.15.7398-7406.2002, 136352, 12097552.
10. Nijhuis M, van Maarseveen NM, Lastere S, Schipper P, Coakley E, Glass B, Rovenska M, de Jong D, Chappey C, Goedegebuure IW, Heilek-Snyder G, Dulude D, Cammack N, Brakier-Gingras L, Konvalinka J, Parkin N, Krausslich HG, Brun-Vezinet F, Boucher CA. A novel substrate-based HIV-1 protease inhibitor drug resistance mechanism. PLoS Med 2007, 4:e36. 10.1371/journal.pmed.0040036, 1769415, 17227139.
11. Shibata J, Sugiura W, Ode H, Iwatani Y, Sato H, Tsang H, Matsuda M, Hasegawa N, Ren F, Tanaka H. Within-host co-evolution of Gag P453L and protease D30N/N88D demonstrates virological advantage in a highly protease inhibitor-exposed HIV-1 case. Antiviral Res 2011, 90:33-41. 10.1016/j.antiviral.2011.02.004, 21338625.
12. Dam E, Quercia R, Glass B, Descamps D, Launay O, Duval X, Krausslich HG, Hance AJ, Clavel F. Gag mutations strongly contribute to HIV-1 resistance to protease inhibitors in highly drug-experienced patients besides compensating for fitness loss. PLoS Pathog 2009, 5:e1000345. 10.1371/journal.ppat.1000345, 2652074, 19300491.
13. van Maarseveen NM, Andersson D, Lepsik M, Fun A, Schipper PJ, de Jong D, Boucher CA, Nijhuis M. Modulation of HIV-1 Gag NC/p1 cleavage efficiency affects protease inhibitor resistance and viral replicative capacity. Retrovirology 2012, 9:29. 10.1186/1742-4690-9-29, 3349524, 22462820.
14. Navia MA, Fitzgerald PM, McKeever BM, Leu CT, Heimbach JC, Herber WK, Sigal IS, Darke PL, Springer JP. Three-dimensional structure of aspartyl protease from human immunodeficiency virus HIV-1. Nature 1989, 337:615-620. 10.1038/337615a0, 2645523.
15. Wlodawer A, Miller M, Jaskolski M, Sathyanarayana BK, Baldwin E, Weber IT, Selk LM, Clawson L, Schneider J, Kent SB. Conserved folding in retroviral proteases: crystal structure of a synthetic HIV-1 protease. Science 1989, 245:616-621. 10.1126/science.2548279, 2548279.
16. Pettit SC, Everitt LE, Choudhury S, Dunn BM, Kaplan AH. Initial cleavage of the human immunodeficiency virus type 1 GagPol precursor by its activated protease occurs by an intramolecular mechanism. J Virol 2004, 78:8477-8485. 10.1128/JVI.78.16.8477-8485.2004, 479095, 15280456.
17. Tang C, Louis JM, Aniana A, Suh JY, Clore GM. Visualizing transient events in amino-terminal autoprocessing of HIV-1 protease. Nature 2008, 455:693-696. 10.1038/nature07342, 2798589, 18833280.
18. Craig JC, Duncan IB, Hockley D, Grief C, Roberts NA, Mills JS. Antiviral properties of Ro 31-8959, an inhibitor of human immunodeficiency virus (HIV) proteinase. Antiviral Res 1991, 16:295-305. 10.1016/0166-3542(91)90045-S, 1810306.
19. Vacca JP, Dorsey BD, Schleif WA, Levin RB, McDaniel SL, Darke PL, Zugay J, Quintero JC, Blahy OM, Roth E, et al. L-735,524: an orally bioavailable human immunodeficiency virus type 1 protease inhibitor. Proc Natl Acad Sci U S A 1994, 91:4096-4100. 10.1073/pnas.91.9.4096, 43730, 8171040.
20. Partaledis JA, Yamaguchi K, Tisdale M, Blair EE, Falcione C, Maschera B, Myers RE, Pazhanisamy S, Futer O, Cullinan AB, et al. In vitro selection and characterization of human immunodeficiency virus type 1 (HIV-1) isolates with reduced sensitivity to hydroxyethylamino sulfonamide inhibitors of HIV-1 aspartyl protease. J Virol 1995, 69:5228-5235. 189353, 7636964.
21. Kempf DJ, Marsh KC, Denissen JF, McDonald E, Vasavanonda S, Flentge CA, Green BE, Fino L, Park CH, Kong XP, et al. ABT-538 is a potent inhibitor of human immunodeficiency virus protease and has high oral bioavailability in humans. Proc Natl Acad Sci U S A 1995, 92:2484-2488. 10.1073/pnas.92.7.2484, 42242, 7708670.
22. Patick AK, Mo H, Markowitz M, Appelt K, Wu B, Musick L, Kalish V, Kaldor S, Reich S, Ho D, Webber S. Antiviral and resistance studies of AG1343, an orally bioavailable inhibitor of human immunodeficiency virus protease. Antimicrob Agents Chemother 1996, 40:292-297. 163104, 8834868.
23. Sham HL, Kempf DJ, Molla A, Marsh KC, Kumar GN, Chen CM, Kati W, Stewart K, Lal R, Hsu A, Betebenner D, Korneyeva M, Vasavanonda S, McDonald E, Saldivar A, Wideburg N, Chen X, Niu P, Park C, Jayanti V, Grabowski B, Granneman GR, Sun E, Japour AJ, Leonard JM, Plattner JJ, Norbeck DW. ABT-378, a highly potent inhibitor of the human immunodeficiency virus protease. Antimicrob Agents Chemother 1998, 42:3218-3224. 106025, 9835517.
24. Robinson BS, Riccardi KA, Gong YF, Guo Q, Stock DA, Blair WS, Terry BJ, Deminie CA, Djang F, Colonno RJ, Lin PF. BMS-232632, a highly potent human immunodeficiency virus protease inhibitor that can be used in combination with other available antiretroviral agents. Antimicrob Agents Chemother 2000, 44:2093-2099. 10.1128/AAC.44.8.2093-2099.2000, 90019, 10898681.
25. Koh Y, Nakata H, Maeda K, Ogata H, Bilcer G, Devasamudram T, Kincaid JF, Boross P, Wang YF, Tie Y, Volarath P, Gaddis L, Harrison RW, Weber IT, Ghosh AK, Mitsuya H. Novel bis-tetrahydrofuranylurethane-containing nonpeptidic protease inhibitor (PI) UIC-94017 (TMC114) with potent activity against multi-PI-resistant human immunodeficiency virus in vitro. Antimicrob Agents Chemother 2003, 47:3123-3129. 10.1128/AAC.47.10.3123-3129.2003, 201142, 14506019.
26. Turner SR, Strohbach JW, Tommasi RA, Aristoff PA, Johnson PD, Skulnick HI, Dolak LA, Seest EP, Tomich PK, Bohanon MJ, Horng MM, Lynn JC, Chong KT, Hinshaw RR, Watenpaugh KD, Janakiraman MN, Thaisrivongs S. Tipranavir (PNU-140690): a potent, orally bioavailable nonpeptidic HIV protease inhibitor of the 5,6-dihydro-4-hydroxy-2-pyrone sulfonamide class. J Med Chem 1998, 41:3467-3476. 10.1021/jm9802158, 9719600.
27. Koh Y, Matsumi S, Das D, Amano M, Davis DA, Li J, Leschenko S, Baldridge A, Shioda T, Yarchoan R, Ghosh AK, Mitsuya H. Potent inhibition of HIV-1 replication by novel non-peptidyl small molecule inhibitors of protease dimerization. J Biol Chem 2007, 282:28709-28720. 10.1074/jbc.M703938200, 17635930.
28. Louis JM, Aniana A, Weber IT, Sayer JM. Inhibition of autoprocessing of natural variants and multidrug resistant mutant precursors of HIV-1 protease by clinical inhibitors. Proc Natl Acad Sci U S A 2011, 108:9072-9077. 10.1073/pnas.1102278108, 3107318, 21576495.
29. Davis DA, Soule EE, Davidoff KS, Daniels SI, Naiman NE, Yarchoan R. Activity of Human Immunodeficiency Virus Type 1 Protease Inhibitors against the Initial Autocleavage in Gag-Pol Polyprotein Processing. Antimicrob Agents Chemother 2012, 56:3620-3628.
30. Palella FJ, Delaney KM, Moorman AC, Loveless MO, Fuhrer J, Satten GA, Aschman DJ, Holmberg SD. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med 1998, 338:853-860. 10.1056/NEJM199803263381301, 9516219.
31. Kempf DJ, Marsh KC, Kumar G, Rodrigues AD, Denissen JF, McDonald E, Kukulka MJ, Hsu A, Granneman GR, Baroldi PA, Sun E, Pizzuti D, Plattner JJ, Norbeck DW, Leonard JM. Pharmacokinetic enhancement of inhibitors of the human immunodeficiency virus protease by coadministration with ritonavir. Antimicrob Agents Chemother 1997, 41:654-660. 163767, 9056009.
32. van Heeswijk RP, Veldkamp A, Mulder JW, Meenhorst PL, Lange JM, Beijnen JH, Hoetelmans RM. Combination of protease inhibitors for the treatment of HIV-1-infected patients: a review of pharmacokinetics and clinical experience. Antivir Ther 2001, 6:201-229.
33. Larder BA, Hertogs K, Bloor S, van den Eynde CH, DeCian W, Wang Y, Freimuth WW, Tarpley G. Tipranavir inhibits broadly protease inhibitor-resistant HIV-1 clinical samples. AIDS 2000, 14:1943-1948. 10.1097/00002030-200009080-00009, 10997398.
34. De Meyer S, Azijn H, Fransen E, De Baere I, Van Ginderen M, Maes B, de Bethune MP. The pathway leading to TMC114 resistance is different for TMC114 compared with other protease inhibitors. Antivir Ther 2006, 11:S24.
35. Surleraux DL, Tahri A, Verschueren WG, Pille GM, de Kock HA, Jonckers TH, Peeters A, De Meyer S, Azijn H, Pauwels R, de Bethune MP, King NM, Prabu-Jeyabalan M, Schiffer CA, Wigerinck PB. Discovery and selection of TMC114, a next generation HIV-1 protease inhibitor. J Med Chem 2005, 48:1813-1822. 10.1021/jm049560p, 15771427.
36. De Meyer S, Azijn H, Surleraux D, Jochmans D, Tahri A, Pauwels R, Wigerinck P, de Bethune MP. TMC114, a novel human immunodeficiency virus type 1 protease inhibitor active against protease inhibitor-resistant viruses, including a broad range of clinical isolates. Antimicrob Agents Chemother 2005, 49:2314-2321. 10.1128/AAC.49.6.2314-2321.2005, 1140553, 15917527.
37. Kolli M, Lastere S, Schiffer CA. Co-evolution of nelfinavir-resistant HIV-1 protease and the p1-p6 substrate. Virology 2006, 347:405-409. 10.1016/j.virol.2005.11.049, 16430939.
38. Prabu-Jeyabalan M, Nalivaika EA, Romano K, Schiffer CA. Mechanism of substrate recognition by drug-resistant human immunodeficiency virus type 1 protease variants revealed by a novel structural intermediate. J Virol 2006, 80:3607-3616. 10.1128/JVI.80.7.3607-3616.2006, 1440387, 16537628.
39. Nalam MN, Ali A, Altman MD, Reddy GS, Chellappan S, Kairys V, Ozen A, Cao H, Gilson MK, Tidor B, Rana TM, Schiffer CA. Evaluating the substrate-envelope hypothesis: structural analysis of novel HIV-1 protease inhibitors designed to be robust against drug resistance. J Virol 2010, 84:5368-5378. 10.1128/JVI.02531-09, 2863851, 20237088.
40. Gulnik SV, Suvorov LI, Liu B, Yu B, Anderson B, Mitsuya H, Erickson JW. Kinetic characterization and cross-resistance patterns of HIV-1 protease mutants selected under drug pressure. Biochemistry 1995, 34:9282-9287. 10.1021/bi00029a002, 7626598.
41. Croteau G, Doyon L, Thibeault D, McKercher G, Pilote L, Lamarre D. Impaired fitness of human immunodeficiency virus type 1 variants with high-level resistance to protease inhibitors. J Virol 1997, 71:1089-1096. 191160, 8995629.
42. Mahalingam B, Louis JM, Reed CC, Adomat JM, Krouse J, Wang YF, Harrison RW, Weber IT. Structural and kinetic analysis of drug resistant mutants of HIV-1 protease. Eur J Biochem 1999, 263:238-245. 10.1046/j.1432-1327.1999.00514.x, 10429209.
43. Borman AM, Paulous S, Clavel F. Resistance of human immunodeficiency virus type 1 to protease inhibitors: selection of resistance mutations in the presence and absence of the drug. J Gen Virol 1996, 77(Pt 3):419-426.
44. Doyon L, Croteau G, Thibeault D, Poulin F, Pilote L, Lamarre D. Second locus involved in human immunodeficiency virus type 1 resistance to protease inhibitors. J Virol 1996, 70:3763-3769. 190252, 8648711.
45. Zhang YM, Imamichi H, Imamichi T, Lane HC, Falloon J, Vasudevachari MB, Salzman NP. Drug resistance during indinavir therapy is caused by mutations in the protease gene and in its Gag substrate cleavage sites. J Virol 1997, 71:6662-6670. 191944, 9261388.
46. Mammano F, Petit C, Clavel F. Resistance-associated loss of viral fitness in human immunodeficiency virus type 1: phenotypic analysis of protease and gag coevolution in protease inhibitor-treated patients. J Virol 1998, 72:7632-7637. 110025, 9696866.
47. Nijhuis M, Schuurman R, de Jong D, Erickson J, Gustchina E, Albert J, Schipper P, Gulnik S, Boucher CA. Increased fitness of drug resistant HIV-1 protease as a result of acquisition of compensatory mutations during suboptimal therapy. AIDS 1999, 13:2349-2359. 10.1097/00002030-199912030-00006, 10597776.
48. Mammano F, Trouplin V, Zennou V, Clavel F. Retracing the evolutionary pathways of human immunodeficiency virus type 1 resistance to protease inhibitors: virus fitness in the absence and in the presence of drug. J Virol 2000, 74:8524-8531. 10.1128/JVI.74.18.8524-8531.2000, 116364, 10954553.
49. Prado JG, Wrin T, Beauchaine J, Ruiz L, Petropoulos CJ, Frost SD, Clotet B, D'Aquila RT, Martinez-Picado J. Amprenavir-resistant HIV-1 exhibits lopinavir cross-resistance and reduced replication capacity. AIDS 2002, 16:1009-1017. 10.1097/00002030-200205030-00007, 11953467.
50. Gupta RK, Kohli A, McCormick AL, Towers GJ, Pillay D, Parry CM. Full-length HIV-1 Gag determines protease inhibitor susceptibility within in vitro assays. AIDS 2010, 24:1651-1655. 10.1097/QAD.0b013e3283398216, 2923069, 20597164.
51. Cote HC, Brumme ZL, Harrigan PR. Human immunodeficiency virus type 1 protease cleavage site mutations associated with protease inhibitor cross-resistance selected by indinavir, ritonavir, and/or saquinavir. J Virol 2001, 75:589-594. 10.1128/JVI.75.2.589-594.2001, 113954, 11134271.
52. de Oliveira T, Engelbrecht S, Janse van Rensburg E, Gordon M, Bishop K, zur Megede J, Barnett SW, Cassol S. Variability at human immunodeficiency virus type 1 subtype C protease cleavage sites: an indication of viral fitness?. J Virol 2003, 77:9422-9430. 10.1128/JVI.77.17.9422-9430.2003, 187406, 12915557.
53. Verheyen J, Knops E, Kupfer B, Hamouda O, Somogyi S, Schuldenzucker U, Hoffmann D, Kaiser R, Pfister H, Kucherer C. Prevalence of C-terminal gag cleavage site mutations in HIV from therapy-naive patients. J Infect 2009, 58:61-67. 10.1016/j.jinf.2008.11.009, 19110315.
54. Verheyen J, Verhofstede C, Knops E, Vandekerckhove L, Fun A, Brunen D, Dauwe K, Wensing AM, Pfister H, Kaiser R, Nijhuis M. High prevalence of bevirimat resistance mutations in protease inhibitor-resistant HIV isolates. AIDS 2010, 24:669-673. 10.1097/QAD.0b013e32833160fa, 19926962.
55. Kolli M, Stawiski E, Chappey C, Schiffer CA. Human immunodeficiency virus type 1 protease-correlated cleavage site mutations enhance inhibitor resistance. J Virol 2009, 83:11027-11042. 10.1128/JVI.00628-09, 2772784, 19706699.
56. Larrouy L, Chazallon C, Landman R, Capitant C, Peytavin G, Collin G, Charpentier C, Storto A, Pialoux G, Katlama C, Girard PM, Yeni P, Aboulker JP, Brun-Vezinet F, Descamps D. Gag mutations can impact virological response to dual-boosted protease inhibitor combinations in antiretroviral-naive HIV-infected patients. Antimicrob Agents Chemother 2010, 54:2910-2919. 10.1128/AAC.00194-10, 2897283, 20439606.
57. Bally F, Martinez R, Peters S, Sudre P, Telenti A. Polymorphism of HIV type 1 gag p7/p1 and p1/p6 cleavage sites: clinical significance and implications for resistance to protease inhibitors. AIDS Res Hum Retroviruses 2000, 16:1209-1213. 10.1089/08892220050116970, 10957718.
58. Lambert-Niclot S, Flandre P, Valantin MA, Peytavin G, Sayon S, Morand-Joubert L, Delaugerre C, Algarte-Genin M, Katlama C, Calvez V, Marcelin AG. Resistant minority species are rarely observed in patients on darunavir/ritonavir monotherapy. J Antimicrob Chemother 2012, 67:1470-1474. 10.1093/jac/dks052, 22396434.
59. Gatanaga H, Suzuki Y, Tsang H, Yoshimura K, Kavlick MF, Nagashima K, Gorelick RJ, Mardy S, Tang C, Summers MF, Mitsuya H. Amino acid substitutions in Gag protein at non-cleavage sites are indispensable for the development of a high multitude of HIV-1 resistance against protease inhibitors. J Biol Chem 2002, 277:5952-5961. 10.1074/jbc.M108005200, 11741936.
60. Aoki M, Venzon DJ, Koh Y, Aoki-Ogata H, Miyakawa T, Yoshimura K, Maeda K, Mitsuya H. Non-cleavage site gag mutations in amprenavir-resistant human immunodeficiency virus type 1 (HIV-1) predispose HIV-1 to rapid acquisition of amprenavir resistance but delay development of resistance to other protease inhibitors. J Virol 2009, 83:3059-3068. 10.1128/JVI.02539-08, 2655547, 19176623.
61. Koh Y, Das D, Leschenko S, Nakata H, Ogata-Aoki H, Amano M, Nakayama M, Ghosh AK, Mitsuya H. GRL-02031, a novel nonpeptidic protease inhibitor (PI) containing a stereochemically defined fused cyclopentanyltetrahydrofuran potent against multi-PI-resistant human immunodeficiency virus type 1 in vitro. Antimicrob Agents Chemother 2009, 53:997-1006. 10.1128/AAC.00689-08, 2650524, 18955518.
62. Parry CM, Kolli M, Myers RE, Cane PA, Schiffer C, Pillay D. Three residues in HIV-1 matrix contribute to protease inhibitor susceptibility and replication capacity. Antimicrob Agents Chemother 2011, 55:1106-1113. 10.1128/AAC.01228-10, 3067102, 21149628.
63. Parry CM, Kohli A, Boinett CJ, Towers GJ, McCormick AL, Pillay D. Gag determinants of fitness and drug susceptibility in protease inhibitor-resistant human immunodeficiency virus type 1. J Virol 2009, 83:9094-9101. 10.1128/JVI.02356-08, 2738216, 19587031.
64. Callebaut C, Stray K, Tsai L, Xu L, Lee W, Cihlar T. In vitro HIV-1 resistance selection to GS8374, a novel phosphonate protease inhibitor: comparison with lopinavir, atazanavir and darunavir. Antivir Ther 2007, 12:S18.
65. Knops E, Daumer M, Awerkiew S, Kartashev V, Schulter E, Kutsev S, Brakier-Gingras L, Kaiser R, Pfister H, Verheyen J. Evolution of protease inhibitor resistance in the gag and pol genes of HIV subtype G isolates. J Antimicrob Chemother 2010, 65:1472-1476. 10.1093/jac/dkq129, 20430786.
66. Dierynck I, De Meyer S, C-V K, Van Marck H, Lathouwers E, Thys K, Maes B, de Bethune MP. Impact of Gag cleavage site mutations on the virological response to darunavir/ritonavir in treatment-experienced patients in POWER 1, 2 and 3. Antivir Ther 2007, 12:S23.
67. Roquebert B, Malet I, Wirden M, Tubiana R, Valantin MA, Simon A, Katlama C, Peytavin G, Calvez V, Marcelin AG. Role of HIV-1 minority populations on resistance mutational pattern evolution and susceptibility to protease inhibitors. AIDS 2006, 20:287-289. 10.1097/01.aids.0000202650.03279.69, 16511425.
68. Doyon L, Tremblay S, Bourgon L, Wardrop E, Cordingley MG. Selection and characterization of HIV-1 showing reduced susceptibility to the non-peptidic protease inhibitor tipranavir. Antiviral Res 2005, 68:27-35. 10.1016/j.antiviral.2005.07.003, 16122817.
69. Fun A, van Maarseveen NM, Pokorna J, Maas RE, Schipper PJ, Konvalinka J, Nijhuis M. HIV-1 protease inhibitor mutations affect the development of HIV-1 resistance to the maturation inhibitor bevirimat. Retrovirology 2011, 8:70. 10.1186/1742-4690-8-70, 3184055, 21864346.
70. Margot NA, Gibbs CS, Miller MD. Phenotypic Susceptibility to Bevirimat in Isolates from HIV-1-Infected Patients without Prior Exposure to Bevirimat. Antimicrob Agents Chemother 2010, 54:2345-2353. 10.1128/AAC.01784-09, 2876391, 20308382.
71. Adamson CS, Ablan SD, Boeras I, Goila-Gaur R, Soheilian F, Nagashima K, Li F, Salzwedel K, Sakalian M, Wild CT, Freed EO. In vitro resistance to the human immunodeficiency virus type 1 maturation inhibitor PA-457 (Bevirimat). J Virol 2006, 80:10957-10971. 10.1128/JVI.01369-06, 1642185, 16956950.
72. Van Baelen K, Salzwedel K, Rondelez E, Van Eygen V, De Vos S, Verheyen A, Steegen K, Verlinden Y, Allaway GP, Stuyver LJ. Susceptibility of human immunodeficiency virus type 1 to the maturation inhibitor bevirimat is modulated by baseline polymorphisms in Gag spacer peptide 1. Antimicrob Agents Chemother 2009, 53:2185-2188. 10.1128/AAC.01650-08, 2681549, 19223634.
73. Zhou J, Chen CH, Aiken C. Human immunodeficiency virus type 1 resistance to the small molecule maturation inhibitor 3-O-(3',3'-dimethylsuccinyl)-betulinic acid is conferred by a variety of single amino acid substitutions at the CA-SP1 cleavage site in Gag. J Virol 2006, 80:12095-12101. 10.1128/JVI.01626-06, 1676313, 17035324.
74. Salzwedel K, Reddick M, Matallana C, Finnegan C, Adamson C, Sakalian M, Stanley D, Martin D, McCallister S, Freed E, Allaway G. Role of Gag polymorphisms in HIV-1 sensitivity to the maturation inhibitor bevirimat. Antivir Ther 2008, 13:A31.
75. Li F, Zoumplis D, Matallana C, Kilgore NR, Reddick M, Yunus AS, Adamson CS, Salzwedel K, Martin DE, Allaway GP, Freed EO, Wild CT. Determinants of activity of the HIV-1 maturation inhibitor PA-457. Virology 2006, 356:217-224. 10.1016/j.virol.2006.07.023, 16930665.
76. Adamson CS, Sakalian M, Salzwedel K, Freed EO. Polymorphisms in Gag spacer peptide 1 confer varying levels of resistance to the HIV- 1 maturation inhibitor bevirimat. Retrovirology 2010, 7:36. 10.1186/1742-4690-7-36, 2873507, 20406463.
77. Myint L, Matsuda M, Matsuda Z, Yokomaku Y, Chiba T, Okano A, Yamada K, Sugiura W. Gag non-cleavage site mutations contribute to full recovery of viral fitness in protease inhibitor-resistant human immunodeficiency virus type 1. Antimicrob Agents Chemother 2004, 48:444-452. 10.1128/AAC.48.2.444-452.2004, 321554, 14742193.
78. Malet I, Roquebert B, Dalban C, Wirden M, Amellal B, Agher R, Simon A, Katlama C, Costagliola D, Calvez V, Marcelin AG. Association of Gag cleavage sites to protease mutations and to virological response in HIV-1 treated patients. J Infect 2007, 54:367-374. 10.1016/j.jinf.2006.06.012, 16875739.
79. Mo H, Parkin N, Stewart KD, Lu L, Dekhtyar T, Kempf DJ, Molla A. Identification and structural characterization of I84C and I84A mutations that are associated with high-level resistance to human immunodeficiency virus protease inhibitors and impair viral replication. Antimicrob Agents Chemother 2007, 51:732-735. 10.1128/AAC.00690-06, 1797770, 17101675.
80. Resch W, Parkin N, Watkins T, Harris J, Swanstrom R. Evolution of human immunodeficiency virus type 1 protease genotypes and phenotypes in vivo under selective pressure of the protease inhibitor ritonavir. J Virol 2005, 79:10638-10649. 10.1128/JVI.79.16.10638-10649.2005, 1182672, 16051856.
81. Nijhuis M, Wensing AM, Bierman WF, de Jong D, Kagan R, Fun A, Jaspers CA, Schurink KA, van Agtmael MA, Boucher CA. Failure of treatment with first-line lopinavir boosted with ritonavir can be explained by novel resistance pathways with protease mutation 76 V. J Infect Dis 2009, 200:698-709. 10.1086/605329, 19627247.
82. Verheyen J, Litau E, Sing T, Daumer M, Balduin M, Oette M, Fatkenheuer G, Rockstroh JK, Schuldenzucker U, Hoffmann D, Pfister H, Kaiser R. Compensatory mutations at the HIV cleavage sites p7/p1 and p1/p6-gag in therapy-naive and therapy-experienced patients. Antivir Ther 2006, 11:879-887.
83. Knops E, Kemper I, Schulter E, Pfister H, Kaiser R, Verheyen J. The evolution of protease mutation 76 V is associated with protease mutation 46I and gag mutation 431 V. AIDS 2010, 24:779-781. 10.1097/QAD.0b013e328336784d, 20139751.
84. Watkins T, Resch W, Irlbeck D, Swanstrom R. Selection of high-level resistance to human immunodeficiency virus type 1 protease inhibitors. Antimicrob Agents Chemother 2003, 47:759-769. 10.1128/AAC.47.2.759-769.2003, 151730, 12543689.
85. Carrillo A, Stewart KD, Sham HL, Norbeck DW, Kohlbrenner WE, Leonard JM, Kempf DJ, Molla A. In vitro selection and characterization of human immunodeficiency virus type 1 variants with increased resistance to ABT-378, a novel protease inhibitor. J Virol 1998, 72:7532-7541. 109995, 9696850.
86. Knops E, Brakier-Gingras L, Schulter E, Pfister H, Kaiser R, Verheyen J. Mutational patterns in the frameshift-regulating site of HIV-1 selected by protease inhibitors. Med Microbiol Immunol 2011, 201:213-218.
87. Yates PJ, Hazen R, St Clair M, Boone L, Tisdale M, Elston RC. In vitro development of resistance to human immunodeficiency virus protease inhibitor GW640385. Antimicrob Agents Chemother 2006, 50:1092-1095. 10.1128/AAC.50.3.1092-1095.2006, 1426426, 16495277.
88. Ghosn J, Delaugerre C, Flandre P, Galimand J, Cohen-Codar I, Raffi F, Delfraissy JF, Rouzioux C, Chaix ML. Polymorphism in Gag Gene Cleavage Sites of HIV-1 Non-B Subtype and Virological Outcome of a First-Line Lopinavir/Ritonavir Single Drug Regimen. PLoS One 2011, 6:e24798. 10.1371/journal.pone.0024798, 3176769, 21949754.
89. Feher A, Weber IT, Bagossi P, Boross P, Mahalingam B, Louis JM, Copeland TD, Torshin IY, Harrison RW, Tozser J. Effect of sequence polymorphism and drug resistance on two HIV-1 Gag processing sites. Eur J Biochem 2002, 269:4114-4120. 10.1046/j.1432-1033.2002.03105.x, 12180988.
90. Prabu-Jeyabalan M, Nalivaika EA, King NM, Schiffer CA. Structural basis for coevolution of a human immunodeficiency virus type 1 nucleocapsid-p1 cleavage site with a V82A drug-resistant mutation in viral protease. J Virol 2004, 78:12446-12454. 10.1128/JVI.78.22.12446-12454.2004, 525094, 15507631.
91. Muller B, Anders M, Akiyama H, Welsch S, Glass B, Nikovics K, Clavel F, Tervo HM, Keppler OT, Krausslich HG. HIV-1 Gag processing intermediates trans-dominantly interfere with HIV-1 infectivity. J Biol Chem 2009, 284:29692-29703. 10.1074/jbc.M109.027144, 2785601, 19666477.
92. Moore ML, Bryan WM, Fakhoury SA, Magaard VW, Huffman WF, Dayton BD, Meek TD, Hyland L, Dreyer GB, Metcalf BW, et al. Peptide substrates and inhibitors of the HIV-1 protease. Biochem Biophys Res Commun 1989, 159:420-425. 10.1016/0006-291X(89)90008-9, 2649094.
93. Briggs JA, Simon MN, Gross I, Krausslich HG, Fuller SD, Vogt VM, Johnson MC. The stoichiometry of Gag protein in HIV-1. Nat Struct Mol Biol 2004, 11:672-675. 10.1038/nsmb785, 15208690.
94. Nijhuis M, van Maarseveen NM, de Jong D, Schipper PJ, Goedegebuure IW, Boucher CAB. Substitutions wihin Gag but outside the cleavage sites can cause protease inhibitor resistance. Antivir Ther 2006, 11:S149.
95. Lastere S, Dalban C, Collin G, Descamps D, Girard PM, Clavel F, Costagliola D, Brun-Vezinet F. Impact of insertions in the HIV-1 p6 PTAPP region on the virological response to amprenavir. Antivir Ther 2004, 9:221-227.
96. Martins AN, Arruda MB, Pires AF, Tanuri A, Brindeiro RM. Accumulation of P(T/S)AP late domain duplications in HIV type 1 subtypes B, C, and F derived from individuals failing ARV therapy and ARV drug-naive patients. AIDS Res Hum Retroviruses 2011, 27:687-692. 10.1089/aid.2010.0282, 21083435.
97. Brumme ZL, Chan KJ, Dong WW, Wynhoven B, Mo T, Hogg RS, Montaner JS, O'Shaughnessy MV, Harrigan PR. Prevalence and clinical implications of insertions in the HIV-1 p6Gag N-terminal region in drug-naive individuals initiating antiretroviral therapy. Antivir Ther 2003, 8:91-96.
98. Gallego O, de Mendoza C, Corral A, Soriano V. Changes in the human immunodeficiency virus p7-p1-p6 gag gene in drug-naive and pretreated patients. J Clin Microbiol 2003, 41:1245-1247. 10.1128/JCM.41.3.1245-1247.2003, 150303, 12624058.
99. Holguin A, Alvarez A, Soriano V. Variability in the P6gag domains of HIV-1 involved in viral budding. AIDS 2006, 20:624-627. 10.1097/01.aids.0000210619.75707.21, 16470130.
100. Kaufmann GR, Suzuki K, Cunningham P, Mukaide M, Kondo M, Imai M, Zaunders J, Cooper DA. Impact of HIV type 1 protease, reverse transcriptase, cleavage site, and p6 mutations on the virological response to quadruple therapy with saquinavir, ritonavir, and two nucleoside analogs. AIDS Res Hum Retroviruses 2001, 17:487-497. 10.1089/08892220151126526, 11350662.
101. Larrouy L, Lambert-Niclot S, Charpentier C, Fourati S, Visseaux B, Soulie C, Wirden M, Katlama C, Yeni P, Brun-Vezinet F, Calvez V, Marcelin AG, Descamps D. Positive impact of HIV-1 gag cleavage site mutations on the virological response to darunavir boosted with ritonavir. Antimicrob Agents Chemother 2011, 55:1754-1757. 10.1128/AAC.01049-10, 3067137, 21282435.
102. Meynard JL, Vray M, Morand-Joubert L, Race E, Descamps D, Peytavin G, Matheron S, Lamotte C, Guiramand S, Costagliola D, Brun-Vezinet F, Clavel F, Girard PM. Phenotypic or genotypic resistance testing for choosing antiretroviral therapy after treatment failure: a randomized trial. AIDS 2002, 16:727-736. 10.1097/00002030-200203290-00008, 11964529.
103. Lambert-Niclot S, Flandre P, Malet I, Canestri A, Soulie C, Tubiana R, Brunet C, Wirden M, Katlama C, Calvez V, Marcelin AG. Impact of gag mutations on selection of darunavir resistance mutations in HIV-1 protease. J Antimicrob Chemother 2008, 62:905-908. 10.1093/jac/dkn338, 18765410.
104. Li S, Hill CP, Sundquist WI, Finch JT. Image reconstructions of helical assemblies of the HIV-1 CA protein. Nature 2000, 407:409-413. 10.1038/35030177, 11014200.
105. Briggs JA, Riches JD, Glass B, Bartonova V, Zanetti G, Krausslich HG. Structure and assembly of immature HIV. Proc Natl Acad Sci U S A 2009, 106:11090-11095. 10.1073/pnas.0903535106, 2700151, 19549863.
106. Tang C, Loeliger E, Kinde I, Kyere S, Mayo K, Barklis E, Sun Y, Huang M, Summers MF. Antiviral inhibition of the HIV-1 capsid protein. J Mol Biol 2003, 327:1013-1020. 10.1016/S0022-2836(03)00289-4, 12662926.
107. Kelly BN, Kyere S, Kinde I, Tang C, Howard BR, Robinson H, Sundquist WI, Summers MF, Hill CP. Structure of the antiviral assembly inhibitor CAP-1 complex with the HIV-1 CA protein. J Mol Biol 2007, 373:355-366. 10.1016/j.jmb.2007.07.070, 2066180, 17826792.
108. Sticht J, Humbert M, Findlow S, Bodem J, Muller B, Dietrich U, Werner J, Krausslich HG. A peptide inhibitor of HIV-1 assembly in vitro. Nat Struct Mol Biol 2005, 12:671-677. 10.1038/nsmb964, 16041387.
109. Zhang H, Zhao Q, Bhattacharya S, Waheed AA, Tong X, Hong A, Heck S, Curreli F, Goger M, Cowburn D, Freed EO, Debnath AK. A cell-penetrating helical peptide as a potential HIV-1 inhibitor. J Mol Biol 2008, 378:565-580. 10.1016/j.jmb.2008.02.066, 2695608, 18374356.
110. Titolo S, Mercier JF, Wardrop E, Schwedler U, Goudreau N, Lemke C, Faucher AM, Yoakim C, Simoneau B, Sundquist WI, Mason S. Discovery of Potent HIV-1 CapsidAssembly Inhibitors 2010, Program & Abstracts of the 17th Conference on Retroviruses and Opportunistic Infections, San Francisco, USA, Abstract 50.
111. Blair WS, Pickford C, Irving SL, Brown DG, Anderson M, Bazin R, Cao J, Ciaramella G, Isaacson J, Jackson L, Hunt R, Kjerrstrom A, Nieman JA, Patick AK, Perros M, Scott AD, Whitby K, Wu H, Butler SL. HIV capsid is a tractable target for small molecule therapeutic intervention. PLoS Pathog 2010, 6:e1001220. 10.1371/journal.ppat.1001220, 3000358, 21170360.
112. Shi J, Zhou J, Shah VB, Aiken C, Whitby K. Small-molecule inhibition of human immunodeficiency virus type 1 infection by virus capsid destabilization. J Virol 2011, 85:542-549. 10.1128/JVI.01406-10, 3014163, 20962083.
113. Bocanegra R, Nevot M, Domenech R, Lopez I, Abian O, Rodriguez-Huete A, Cavasotto CN, Velazquez-Campoy A, Gomez J, Martinez MA, Neira JL, Mateu MG. Rationally Designed Interfacial Peptides Are Efficient In Vitro Inhibitors of HIV-1 Capsid Assembly with Antiviral Activity. PLoS One 2011, 6:e23877. 10.1371/journal.pone.0023877, 3169566, 21931621.
114. Li F, Goila-Gaur R, Salzwedel K, Kilgore NR, Reddick M, Matallana C, Castillo A, Zoumplis D, Martin DE, Orenstein JM, Allaway GP, Freed EO, Wild CT. PA-457: a potent HIV inhibitor that disrupts core condensation by targeting a late step in Gag processing. Proc Natl Acad Sci U S A 2003, 100:13555-13560. 10.1073/pnas.2234683100, 263852, 14573704.
115. Nguyen AT, Feasley CL, Jackson KW, Nitz TJ, Salzwedel K, Air GM, Sakalian M. The prototype HIV-1 maturation inhibitor, bevirimat, binds to the CA-SP1 cleavage site in immature Gag particles. Retrovirology 2011, 8:101. 10.1186/1742-4690-8-101, 3267693, 22151792.
116. Keller PW, Adamson CS, Heymann JB, Freed EO, Steven AC. HIV-1 maturation inhibitor bevirimat stabilizes the immature Gag lattice. J Virol 2011, 85:1420-1428. 10.1128/JVI.01926-10, 3028903, 21106735.
117. Kilgore NR, Reddick M, Zuiderhof M, Stanley D, Nitz T, Bullock P, Allaway GP, Martin DE. Characterization of PA1050040, a second-generation HIV-1 maturation inhibitor 2007, IAS 2007, 4th IAS Conference On HIV Pathogenesis, Treatment and Prevention, Sydney, Australia, Abstract MOPDX05.
118. Beelen AP, Otto J, Fidler M, Sanguinetti E, Smiley P, Balch A, Medlock M, Jackson M, Swabb EA. Phase 1, Single Ascending Oral Dose Study of the Safety, Tolerability, and Pharmacokinetics of a Novel HIV-1 Maturation Inhibitor in HIV Negative Healthy Subjects 2009, Program & Abstracts of the 16th Conference on Retroviruses and Opportunistic Infections, Montreal, Canada, Abstract 570.
119. Baichwal V, Austin H, Brown B, McKinnon R, Yager K, Kumar V, Gerrish D, Anderson M, Carlson R. Anti-viral Characterization in vitro of a Novel Maturation Inhibitor, MPC-9055 2009, Program & Abstracts of the 16th Conference on Retroviruses and Opportunistic Infections, Montreal, Canada, Abstract 561.
120. Kumar V, Gerrish D, Hoarau C, Yager K, Austin H, McKinnon R, Brown B, Baichwal V, Papac D, Bradford C, Patton S, Bulka K, DeMie L, Carlson R. Next Generation Orally Bioavailable HIV-1 Maturation Inhibitors 2010, 239th ACS National Meeting & Exposition, San Francisco, USA, Abstract 137.
121. Blair WS, Cao J, Fok-Seang J, Griffin P, Isaacson J, Jackson RL, Murray E, Patick AK, Peng Q, Perros M, Pickford C, Wu H, Butler SL. New small-molecule inhibitor class targeting human immunodeficiency virus type 1 virion maturation. Antimicrob Agents Chemother 2009, 53:5080-5087. 10.1128/AAC.00759-09, 2786326, 19805571.
122. McCallister S, Lalezari J, Richmond G, Thompson M, Harrigan PR, Martin DE, Salzwedel K, Allaway GP. HIV-1 Gag polymorphisms determine treatment response to bevirimat (PA-457). Antivir Ther 2008, 13:A10.
123. Knapp DJ, Harrigan PR, Poon AF, Brumme ZL, Brockman M, Cheung PK. In Vitro Selection of Clinically Relevant Bevirimat Resistance Mutations Revealed by " Deep" Sequencing of Serially Passaged, Quasispecies-Containing Recombinant HIV-1. J Clin Microbiol 2011, 49:201-208. 10.1128/JCM.01868-10, 3020451, 21084518.
124. Seclen E, Gonzalez Mdel M, Corral A, de Mendoza C, Soriano V, Poveda E. High prevalence of natural polymorphisms in Gag (CA-SP1) associated with reduced response to Bevirimat, an HIV-1 maturation inhibitor. AIDS 2010, 24:467-469. 10.1097/QAD.0b013e328335ce07, 19996935.
125. Lu W, Salzwedel K, Wang D, Chakravarty S, Freed EO, Wild CT, Li F. A single polymorphism in HIV-1 subtype C SP1 is sufficient to confer natural resistance to the maturation inhibitor bevirimat. Antimicrob Agents Chemother 2011, 55:3324-3329. 10.1128/AAC.01435-10, 3122462, 21502630.
126. Malet I, Wirden M, Derache A, Simon A, Katlama C, Calvez V, Marcelin AG. Primary genotypic resistance of HIV-1 to the maturation inhibitor PA-457 in protease inhibitor-experienced patients. AIDS 2007, 21:871-873. 10.1097/QAD.0b013e3280b079d9, 17415044.
127. Adamson CS, Waki K, Ablan SD, Salzwedel K, Freed EO. Impact of human immunodeficiency virus type 1 resistance to protease inhibitors on evolution of resistance to the maturation inhibitor bevirimat (PA-457). J Virol 2009, 83:4884-4894. 10.1128/JVI.02659-08, 2682084, 19279107.